U.S., May 27 -- ClinicalTrials.gov registry received information related to the study (NCT07605962) titled 'Phase 1/2 Study of UI-102 in Selected Advanced Cancers' on May 18.
Brief Summary: This phase 1/2 first-in-human study is designed to assess the safety and efficacy of UI-102, a TLR7/8 agonist encapsulated in a Cholesteryl Pullulan Nanoparticle.
Study Start Date: May 25
Study Type: INTERVENTIONAL
Condition:
Advanced Cancer
Intervention:
DRUG: UI-102
Specified dose on specified days
Recruitment Status: NOT_YET_RECRUITING
Sponsor: United Immunity, co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....